U.S. markets open in 23 minutes

Osmotica Pharmaceuticals plc (OSMT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8400-0.0600 (-3.16%)
At close: 4:00PM EDT
1.8599 +0.02 (+1.08%)
Pre-Market: 08:43AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close1.9000
Bid1.8300 x 1200
Ask1.8600 x 1800
Day's Range1.8300 - 1.9200
52 Week Range1.8300 - 6.3800
Avg. Volume659,767
Market Cap153.228M
Beta (5Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-1.4480
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for OSMT

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Osmotica Pharmaceuticals plc
    Daily – Vickers Top Buyers & Sellers for 06/08/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • GlobeNewswire

    Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering

    BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares, at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share

  • Benzinga

    Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide

    Midway through trading Thursday, the Dow traded up 1.51% to 34,938.25 while the NASDAQ rose 1.64% to 14,739.43. The S&P also rose, gaining 1.41% to 4,425.22. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 44,059,040 cases with around 707,780 deaths. India confirmed a total of at least 33,894,310 cases and 449,850 deaths, while Brazil reported over 21,516,960 COVID-19 cases with 599,350 deaths. In total, there were at least 236,571,580 cases of

  • GlobeNewswire

    Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million

    BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by Athyrium Capital Management (“Athyrium”). “This financing provides the Company with additional cash to support the commercialization of Upneeq®,” stated Brian Markison, Chief Executive Officer. “We ar